Rockwell Medical has announced positive results from PRIME clinical study of iron-delivery drug, Soluble Ferric Pyrophosphate (SFP), demonstrating statistically significant 37% reduction in erythropoietin stimulating agents (ESA) dose.

The investigational iron-delivery drug SFP is presently in Phase 3 studies for the treatment of iron deficiency in hemodialysis patients.

PRIME study demonstrated that regular SFP-iron administration by means of dialysate reduced the usage of ESAs during hemodialysis while preserving iron balance and enhancing iron delivery, which is the primary endpoint of the study.

Rockwell chairman, CEO and president Robert Chioini said, "SFP's ability to substantially reduce ESA use in the treatment of anemia should translate into significant cost savings in dialysis care while potentially lowering the serious risks associated with the dosing of ESAs."